Among 586 men in Health Professionals Follow-up Study (mean age, 63.8 years; <1% with osteoporosis), higher levels of osteocalcin (odds ratio, 0.37 [95% CI, 0.13-1.04] for quintile 5 vs quintile 1; P for trend = .02) and sclerostin (odds ratio, 0.22 [95% CI, 0.09-0.54] for quintile 5 vs quintile 1; P for trend < .001) were associated with lower risk of hip fracture; however, addition of sclerostin to clinical models predicting incident hip fracture provided limited additional predictive value. The gene discussed is SOST; the disease is hip fracture.